{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:56:32Z","timestamp":1789721792516,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,17]],"date-time":"2022-09-17T00:00:00Z","timestamp":1663372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP19K09828"],"award-info":[{"award-number":["JP19K09828"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ajog.2022.09.024","type":"journal-article","created":{"date-parts":[[2022,9,20]],"date-time":"2022-09-20T11:24:44Z","timestamp":1663673084000},"page":"207.e1-207.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists"],"prefix":"10.1016","volume":"228","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0230-1179","authenticated-orcid":false,"given":"Koichi","family":"Nagai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryoko","family":"Asano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futoshi","family":"Sekiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikiko","family":"Asai-Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohei","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Miyagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2022.09.024_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2020.07.032","article-title":"Predictors of response for elagolix with add-back therapy in women with heavy menstrual bleeding associated with uterine fibroids","volume":"224","author":"Al-Hendy","year":"2021","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib2","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/j.fertnstert.2019.07.013","article-title":"Relugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women","volume":"112","author":"Osuga","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/S1074-3804(05)60254-X","article-title":"GnRH agonist treatment before total laparoscopic hysterectomy for large uteri","volume":"10","author":"Seracchioli","year":"2003","journal-title":"J\u00a0Am Assoc Gynecol Laparosc"},{"key":"10.1016\/j.ajog.2022.09.024_bib4","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/S0015-0282(16)56750-8","article-title":"Absence of a dose-response effect of leuprolide acetate on leiomyomata uteri size","volume":"61","author":"Kiltz","year":"1994","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib5","first-page":"CD000547","article-title":"Preoperative medical therapy before surgery for uterine fibroids","volume":"11","author":"Lethaby","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ajog.2022.09.024_bib6","first-page":"720","article-title":"Treatment of leiomyomata uteri with leuprolide acetate depot: a double-blind, placebo-controlled, multicenter study. The leuprolide Study Group","volume":"77","author":"Friedman","year":"1991","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib7","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0015-0282(16)55189-9","article-title":"Predictors of uterine volume reduction in women with myomas treated with a gonadotropin-releasing hormone agonist","volume":"58","author":"Friedman","year":"1992","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib8","first-page":"107","article-title":"Prediction of histopathologic features and proliferative activity of uterine leiomyoma by magnetic resonance imaging prior to GnRH analogue therapy: correlation between T2-weighted images and effect of GnRH analogue","volume":"21","author":"Oguchi","year":"1995","journal-title":"J\u00a0Obstet Gynaecol (Tokyo 1995)"},{"key":"10.1016\/j.ajog.2022.09.024_bib9","doi-asserted-by":"crossref","first-page":"656","DOI":"10.3109\/02841859909175606","article-title":"Predicting the effect of gonadotropin-releasing hormone (GnRH) analogue treatment on uterine leiomyomas based on MR imaging","volume":"40","author":"Matsuno","year":"1999","journal-title":"Acta Radiol"},{"key":"10.1016\/j.ajog.2022.09.024_bib10","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1093\/humrep\/16.9.1989","article-title":"Value of magnetic resonance imaging in predicting efficacy of GnRH analogue treatment for uterine leiomyoma","volume":"16","author":"Takahashi","year":"2001","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2022.09.024_bib11","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0015-0282(02)03062-5","article-title":"Prediction of the effects of gonadotropin-releasing hormone agonist therapy in uterine leiomyoma by T1 contrast-enhanced magnetic resonance imaging sequences","volume":"77","author":"Kadowaki","year":"2002","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1148\/radiol.2483071288","article-title":"Semiquantitative assessment of MR imaging in prediction of efficacy of gonadotropin-releasing hormone agonist for volume reduction of uterine leiomyoma: initial experience","volume":"248","author":"Okuda","year":"2008","journal-title":"Radiology"},{"key":"10.1016\/j.ajog.2022.09.024_bib13","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1056\/NEJMoa2008283","article-title":"Treatment of uterine fibroid symptoms with relugolix combination therapy","volume":"384","author":"Al-Hendy","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.09.024_bib14","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1056\/NEJMoa1904351","article-title":"Elagolix for heavy menstrual bleeding in women with uterine fibroids","volume":"382","author":"Schlaff","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.09.024_bib15","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.fertnstert.2019.09.037","article-title":"Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture","volume":"112","author":"Sauerbrun-Cutler","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib16","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/0002-9378(90)90440-I","article-title":"Gonadotropin-releasing hormone agonists and estrogen-progestogen replacement therapy","volume":"162","author":"Barbieri","year":"1990","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib17","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1093\/oxfordjournals.humrep.a138762","article-title":"Long-term medical therapy for leiomyomata uteri: a prospective, randomized study of leuprolide acetate depot plus either oestrogen-progestin or progestin \u2018add-back\u2019 for 2 years","volume":"9","author":"Friedman","year":"1994","journal-title":"Hum Reprod"},{"key":"10.1016\/j.ajog.2022.09.024_bib18","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bpobgyn.2017.10.001","article-title":"Alternatives to hysterectomy: the burden of fibroids and the quality of life","volume":"46","author":"Fortin","year":"2018","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib19","first-page":"S2","article-title":"Direct costs incurred among women undergoing surgical procedures to treat uterine fibroids","volume":"26","author":"Harrington","year":"2020","journal-title":"J\u00a0Manag Care Spec Pharm"},{"key":"10.1016\/j.ajog.2022.09.024_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.12.002","article-title":"The estimated annual cost of uterine leiomyomata in the United States","volume":"206","author":"Cardozo","year":"2012","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib21","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/j.ajog.2006.02.020","article-title":"Health care resource use for uterine fibroid tumors in the United States","volume":"195","author":"Flynn","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib22","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1080\/03007995.2019.1642186","article-title":"Healthcare resource utilization and costs among women diagnosed with uterine fibroids compared to women without uterine fibroids","volume":"35","author":"Shih","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ajog.2022.09.024_bib23","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1126\/science.1208930","article-title":"MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas","volume":"334","author":"M\u00e4kinen","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ajog.2022.09.024_bib24","doi-asserted-by":"crossref","first-page":"4857","DOI":"10.1038\/s41467-019-12536-4","article-title":"Genome-wide association and epidemiological analyses reveal common genetic origins between uterine leiomyomata and endometriosis","volume":"10","author":"Gallagher","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.ajog.2022.09.024_bib25","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.37110","article-title":"Genetic predisposition to uterine leiomyoma is determined by loci for genitourinary development and genome stability","volume":"7","author":"V\u00e4lim\u00e4ki","year":"2018","journal-title":"Elife"},{"key":"10.1016\/j.ajog.2022.09.024_bib26","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.fertnstert.2014.06.040","article-title":"MED12 mutation frequency in unselected sporadic uterine leiomyomas","volume":"102","author":"Heinonen","year":"2014","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib27","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1016\/j.fertnstert.2021.05.081","article-title":"Tryptophan catabolism is dysregulated in leiomyomas","volume":"116","author":"Chuang","year":"2021","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.ajog.2015.02.016","article-title":"Aberrant expression of erythropoietin in uterine leiomyoma: implications in tumor growth","volume":"213","author":"Asano","year":"2015","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2022.09.024_bib29","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.fertnstert.2018.09.014","article-title":"Expression of erythropoietin messenger ribonucleic acid in wild-type MED12 uterine leiomyomas under estrogenic influence: new insights into related growth disparities","volume":"111","author":"Asano","year":"2019","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib30","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/humu.22612","article-title":"Mutations in exon 1 highlight the role of MED12 in uterine leiomyomas","volume":"35","author":"K\u00e4mpj\u00e4rvi","year":"2014","journal-title":"Hum Mutat"},{"key":"10.1016\/j.ajog.2022.09.024_bib31","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.fertnstert.2012.05.013","article-title":"Prediction of the shrinking rate of uterine leiomyoma nodules using needle biopsy specimens","volume":"98","author":"Kasai","year":"2012","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib32","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0015-0282(97)00273-2","article-title":"Correlation between shrinkage of uterine leiomyoma treated with Buserelin acetate and histopathologic findings of biopsy specimen before treatment","volume":"68","author":"Kawamura","year":"1997","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib33","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/S0015-0282(98)00193-9","article-title":"Does pelvic magnetic resonance imaging differentiate among the histologic subtypes of uterine leiomyomata?","volume":"70","author":"Schwartz","year":"1998","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejogrb.2019.08.002","article-title":"Differences in fibroid vascularity after three months of pre-treatment with leuprolide acetate or ulipristal acetate: a pilot study","volume":"245","author":"Frijlingh","year":"2020","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ajog.2022.09.024_bib35","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1210\/jc.2017-02295","article-title":"Matrix metalloproteinase activity correlates with uterine myoma volume reduction after ulipristal acetate treatment","volume":"103","author":"Courtoy","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ajog.2022.09.024_bib36","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.fertnstert.2015.04.025","article-title":"In\u00a0vivo mechanisms of uterine myoma volume reduction with ulipristal acetate treatment","volume":"104","author":"Courtoy","year":"2015","journal-title":"Fertil Steril"},{"key":"10.1016\/j.ajog.2022.09.024_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7150\/ijms.21856","article-title":"Analysis of MED12 mutation in multiple uterine leiomyomas in South Korean patients","volume":"15","author":"Lee","year":"2018","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.ajog.2022.09.024_bib38","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41598-017-01199-0","article-title":"Multiple clinical characteristics separate MED12-mutation-positive and -negative uterine leiomyomas","volume":"7","author":"Heinonen","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ajog.2022.09.024_bib39","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s43032-021-00473-x","article-title":"Frequency of MED12 mutation in relation to tumor and patient\u2019s clinical characteristics: a meta-analysis","volume":"29","author":"He","year":"2022","journal-title":"Reprod Sci"},{"key":"10.1016\/j.ajog.2022.09.024_bib40","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1056\/NEJMoa1302736","article-title":"Characterization of uterine leiomyomas by whole-genome sequencing","volume":"369","author":"Mehine","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2022.09.024_bib41","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.fertnstert.2018.10.022","article-title":"Growth disparities in uterine leiomyomas associated with MED12 mutation","volume":"111","author":"Ferrero","year":"2019","journal-title":"Fertil Steril"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822007487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937822007487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:08:13Z","timestamp":1777392493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937822007487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0002937822007487"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2022.09.024","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"MED12 mutations in uterine leiomyomas: prediction of volume reduction by gonadotropin-releasing hormone agonists","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2022.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}